Table 1 Summary of findings
Author and Year | Patients/NTG patients | Glaucoma type | Operational Styles | Assessed Points | ||
|---|---|---|---|---|---|---|
Emil Nasyrov, 2024 | 23/23 | NTG | XEN-45 gel stent implantation | IOP, Meds, C/O | ||
Ali Salimi, 2021 | 124/NA | All types | iStent injection + P/I | IOP, Meds | ||
Ali Salimi, 2020 | 62/62 | NTG | iStent injection + P/I | IOP, Meds | ||
Koji Nitta, 2020 | 73/16 | NTG | iStent injection + P/I | IOP, Meds | ||
Kyoko Ishida, 2017 | 63/15 | POAG(NTG) | EXPRESS filter device | IOP | ||
Masaru Inatani, 2022 | 232/64 | POAG(NTG) | iStent injection + P/I | IOP, Meds, C/O | ||
Colin Clement, 2020 | 340/20 | POAG(NTG) | iStent injection + P/I | IOP | ||
Enchi Kristina Chang, 2021 | 45/45 | NTG | iStent injection/KDB/ECP+P/I | IOP, Meds | ||
Sabine Baumgarten, 2022 | 55/11 | HTG(NTG) | SBG+ P/I | IOP, Meds | ||
Bryan Chin Hou Ang, 2022 | 30/30 | NTG | iStent injection+ P/I | IOP, Meds | ||
Makoto Aihara,2019 | 37/37 | NTG | EXPRESS filter device +/- P/I | IOP, C/O | ||
Preoperation IOP(mmHg) | Postoperation IOP(mmHg) | Reduction rate/amount of reduction | Preoperation Medications | Postoperation Medications | Reduction rate/amount of reduction | Follow-up time |
19.3 ± 2.0 | 12.7 ± 2.5 | 34% | 2.3 ± 1.3 | 1.5 ± 1.5 | 35% | 5 Year |
16.90±3.85 | 13.17±2.83 | 22% | 2.38±1.29 | 0.16 ± 1.22 | 51% | 3 Year |
15.82±2.94 | 12.32±2.58 | 22% | 1.50±1.28 | 0.45 ± 0.86 | 70% | 1 Year |
14.4±3.0 | 12.8±1.4 | 18% | 2.38 ±0.72 | 0.31±0.70 | 87% | 2 Year |
17.7±4.3 | 11.2±3.6 | 34% | 3.5 ± 0.7 | 0.4 ± 0.8 | 89% | 1 Year |
15.3±2.6 | 13.5±2.3 | 12% | 2.0±1.0 | 0.1±0.04 | 95% | 2 Year |
16.4±4.7 | 13.7±3.1 | 16% | 1.49±1.20 | 0.49±0.95 | 67% | 2 Year |
13.7± 2.2 | 11.9 ± 1.9 | 13% | 2.0 ± 1.1 | 1.1±1.1 | 45% | 24.1 Month |
14.0 ± 2.3 | 12.4 ± 2.3 | 11% | 1.6 ± 0.7 | 0.3 ± 0.7 | 81% | 2-6 Month |
14.4 ± 3.4 | 13.5 ± 3.4 | 6% | 1.3 ± 0.7 | 1.2 ± 1.0 | 8% | 12 Month |
14.8 ± 2.3 | 10.0 ± 3.1 | 32% | 3.3 ± 1.0 | 0.1 ± 0.4 | 97% | 12 Month |